Our preclinical studies demonstrated that EMP3 drives the infiltration of M2 TAMs into GBM, suppresses CD4+ and CD8+ T cell infiltration, and has the potential be exploited as a therapeutic target. The gene discussed is EMP3; the disease is glioblastoma.